Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
The University of Texas Medical Branch, Galveston · with Cancer Prevention Research Institute of Texas · NCT05672927
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 27–45 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 4
- Target enrollment
- 618
- US sites recruiting
- 1
- Study start
- January 18, 2023
- Record last updated
- September 15, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Being studied: 9-valent HPV vaccine, 2 doses alternate timing; 9-valent HPV vaccine, 3 doses standard timing
Conditions: Immunization; HPV Infection; Human Papillomavirus
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion criteria
- Females 27-45 years old.
- Ability to give informed consent.
- Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record.
- Reliable telephone access for the duration of the project.
- Can read and speak in either English or Spanish.
- Identified source of funding for vaccine such as Medicaid, private health insurance, Texas Healthy Women program, etc.
- Reports consistent use of reliable birth control and plans to continue its use through study month 13.
Exclusion criteria
- Currently pregnant or plans to become pregnant or donate eggs in the next 13 months. Any subjects with positive pregnancy tests at the initial visit will be disqualified from the study and advised to seek prenatal care.
- Has an immunodeficiency or autoimmune disease such as HIV infection, lymphoma, leukemia, lupus, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.
- Currently receiving treatment or medication that can suppress immune function including radiation therapy, chemotherapy, cyclosporin, leflunomide (Arava), TNF-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan]), intravenous gamma globulin (IVIG), antilymphocyte sera, other therapy known to interfere with the immune response, or systemic corticosteroids (by mouth or intramuscular injection). Those using or have used steroids that are inhaled, placed in the eye, applied on the skin, or injected into the joint/soft tissue will be considered eligible for the study.
- History of splenectomy
- Known allergies to any vaccine components, including aluminum, yeast or Benzonase.
- Febrile at ≥100°F in the 24 hours prior to vaccination. The patients may be rescheduled for a later date.
- History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- History of >10 sexual partners in their lifetime at time of enrollment
- Plans to move out of the Galveston/Houston area in the 13 months following study entry.
Recruiting US locations
University of Texas Medical Branch
Galveston, TX 77555
Site contact: Rosalina M Trujillo · 409-747-5594 · rmtrujil@UTMB.EDU
Study contacts (from the official record)
- Abbey B Berenson, MD, PhD · 409-772-2417 · abberens@utmb.edu
- Rosalina M Trujillo · 409-747-5594 · rmtrujil@utmb.edu
Similar studies in Texas
All vaccine studies in Texas →- RecruitingHealthy volunteersPhase 1
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
BioNTech SE
- Location
- Houston, TX
- Eligibility basics
- Ages 18–50
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Austin, TX + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Merck Sharp & Dohme LLC
- Location
- Carrollton, TX + 14 other US sites
- Eligibility basics
- Ages 2 mo–1
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
GlaxoSmithKline
- Location
- Weatherford, TX + 5 other US sites
- Eligibility basics
- Ages 18–64